Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags

Author(s):  Nalenz Heiko, Köpf Ellen, Dietel Elke

Issue:  Sep/Oct 2018 - Volume 22, Number 5
View All Articles in Issue

Page(s):  417-423

Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 1
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 2
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 3
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 4
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 5
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 6
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags Page 7

Download in electronic PDF format for $75

Abstract:  Herceptin is a humanized monoclonal antibody that selectively binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2). Herceptin has an important role in the treatment of HER2-positive breast cancer when used in the neoadjuvant, adjuvant, and metastatic settings, and in the treatment of HER2-positive metastatic gastric cancer, and gastroesophageal junction adenocarcinoma. Prior to intravenous infusion, Herceptin must be reconstituted with sterile water for injection and then diluted in intravenous bags with normal saline. The objective of this study was to test the in-use physicochemical stability of the Herceptin drug product after dilution in 0.9% sodium chloride in commercial polyvinylchloride, and polyolefin/ polyethylene/polypropylene infusion bags over the course of a 7-day storage at 2°C to 8°C followed by 24 hours of storage at 30°C with ambient light exposure. Three batches of Herceptin were reconstituted to yield a 21-mg/mL solution that was stored for 48 hours at 2°C to 8°C prior to dilution with 0.9% sodium chloride to create low (0.24-mg/mL) and high (3.84-mg/mL) concentration solutions that were then tested in simulated infusions with a polyvinylchloride or polyolefin/polyethylene/polypropylene infusion bag. Samples for analysis were obtained immediately after dilution of the reconstituted solution (T0), after 7 days of storage at 5°C (T7), after 1 further day of storage at 30°C (T7+1), and after administration through intravenous tubing (Tend). Control samples were obtained from bags containing only 0.9% sodium chloride at each time point. For experiments with both infusion bags, all samples were practically free from particles, were colorless, and had low numbers of subvisible particles with no differences between control and experimental samples. No change in turbidity was detected between T0 and Tend for low and high-concentration samples for each batch. The pH values remained consistent between T0 and T7+1, and osmolality values were consistent across low-concentration and high-concentration samples. Protein content, size, and potency remained consistent throughout storage and simulated infusion. In conclusion, Herceptin remains physicochemically stable for 7 days when stored at 2°C to 8°C, followed by an additional 24 hours at 30°C when diluted in 0.9% sodium chloride and stored in commercially available polyvinylchloride or polyolefin/polyethylene/polypropylene infusion bags.

Related Keywords: Heiko Nalenz, PhD, Ellen Köpf, PhD, Elke Dietel, PhD, herceptin, human epidermal growth factor receptor 2, HER2 antibody, HER2-positive breast cancer, HER2-positive gastric cancer, gastroesophageal junction adenocarcinoma, polyvinylchloride infusion bags, polyolefin/polyethylene/polypropylene infusion bags, compatability, physical stability, chemical stability

Related Categories: CANCER AND AIDS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Prolonged In-use Stability of Reconstituted Herceptin in Commercial Intravenous Bags
Nalenz Heiko
, Köpf Ellen, Dietel Elke
Sep/Oct 2018
Pg. 417-423

Prolonged In-use Stability of Diluted Atezolizumab in Commercial Intravenous Bags
Hui Ada
, Yin Jian, Liu Wei, Zheng Kai
May/Jun 2021
Pg. 246-257

Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Providing Positive Outcomes through Compounding for Animal Cancer Patients
Davidson Gigi S
Jul/Aug 2000
Pg. 264-272

Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials
Mueller Claudia
, Dietel Elde, Heynen Severin R, Nalenz Heiko, Goldbach Pierre, Mahler Hanns-Christian, Schmidt Johannes, Grauschopf Ulla, Schoenhammer Karin
May/Jun 2015
Pg. 261-267

In-use Stability of Ceftaroline Fosamil in Elastomeric Home Infusion Systems and MINI-BAG Plus Containers
Bhattacharya Sisir
, Parekh Satish, Dedhiya Mahendra
Sep/Oct 2015
Pg. 432-436

Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves
, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2022
Pg. 336-341

Stability of Dexmedetomidine in 0.9% Sodium Chloride in Two Types of Intravenous Infusion Bags
Marquis Kathleen
, Hohlfelder Benjamin, Szumita Paul M
Sep/Oct 2017
Pg. 436-439

The Hormonal Link to Breast Cancer: The Estrogen Matrix
Zava David T
Jul/Aug 2002
Pg. 250-254

Zinc Content of Commercial Diluents Widely Use in Drug Admixtures Prepared for Intravenous Infusion
Desai Narendra R
, Shah Syed M, Koczone Julianna, Vencl-Joncic Maja, Sisto Christopher, Ludwig Stephen A
Sep/Oct 2007
Pg. 426-432

The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
Community Pharmacy Addresses the Need for Proper Drug Disposal with Positive Response
Briggs Valerie
Sep/Oct 2010
Pg. 366-369

Stability of Ampicillin Sodium, Nafcillin Sodium, and Oxacillin Sodium in AutoDose Infusion System Bags
Zhang Yanping
, Trissel Lawrence A
May/Jun 2002
Pg. 226-229

Intravenous Admixture Preparation Considerations, Part 2: Incompatibilities and Factors Involved
Allen Loyd V Jr
Jan/Feb 2020
Pg. 44-50

Stability of Gentamicin Sulfate and Tobramycin Sulfate in AutoDose Infusion System Bags
Xu Quanyun A
, Trissel Lawrence A, Saenz Christopher A, Ingram Delshalonda S
Mar/Apr 2002
Pg. 152-154

Panitumumab 2.5-mg/mL in 0.9% Sodium Chloride Injection
Allen Loyd V Jr
Sep/Oct 2010
Pg. 428

Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review
Ruiz Andres D
, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R
Jul/Aug 2011
Pg. 290-300

Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications
Zur Eyal
Nov/Dec 2018
Pg. 446-454

Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George
, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
Jan/Feb 2018
Pg. 86-94

Return to Top